Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
84 participants
INTERVENTIONAL
2025-11-03
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All participants
EEG measure of visual processing
Non-invasive scalp EEG measure of early cortical visual processing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EEG measure of visual processing
Non-invasive scalp EEG measure of early cortical visual processing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-65
* 20/32 visual acuity or better (using in-house optical correction, if necessary)
* An ability to speak English well enough to complete study assessments and to consent to the study
* Subjects with Schizophrenia-Spectrum Disorder
* Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
* Subjects with Bipolar Disorder
* Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).
Exclusion Criteria
* Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:
* Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
* Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
* Actively intoxicated, as shown via patient self-report or staff report;
* Substance use disorder in the past 3 months;
* Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
* Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
* Being in a current manic state
* Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
* Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
* Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
* Lazy eye or squint or other known ocular pathology
* Healthy Control Subjects
* Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
* Case-match Control Non-ill Subjects
* Any lifetime psychotic disorder (as assessed by SCID/or SSD);
* Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
* Persistent threshold psychotic symptoms
* History of psychiatric hospitalization;
* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days
* First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
* Bipolar Subjects
* Persistent threshold psychotic symptoms
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edmund Lalor
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Edmund Lalor, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00007500
Identifier Type: -
Identifier Source: org_study_id